Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

17Buy

5Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$814Upside to Avg. PT+10.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$758→$779
Oct 6, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$900→$950
Oct 1, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$870→$930
Oct 1, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$850
Sep 29, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$737
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$800→$920
Aug 17, 2026	Leerink Partners	David Risinger	PT Raise	Market Perform	$641→$824
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$700→$740
Aug 3, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$1000→$1030
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$696→$737
Jul 31, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$730→$758
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$750→$795
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$700→$750
Jul 31, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$769→$772
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$995→$1000
Jul 9, 2026	Piper Sandler	Biren Amin	PT Cut	Overweight	$855→$854
Jul 8, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$788→$730
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$707→$696

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.

Benzinga Newsdesk

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.

Avi Kapoor

Regeneron Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

Regeneron Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PROJP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PROJefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930